Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lower dose of painkiller works just as well for acute muscle pain in military ER

NCT ID NCT04763876

Symptom relief Sponsor: William Beaumont Army Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a lower dose (15 mg) of the painkiller ketorolac works as well as a higher dose (60 mg) for treating sudden muscle pain in a military emergency department. 110 adults with acute muscle pain received one injection of either dose. The results showed that the lower dose was just as effective at reducing pain after 60 minutes, with no major safety concerns.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

110 people

The number who actually took part.

Started

Jun 2020

Finished

Feb 2021

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Tricare beneficiaries between 18-55 years of age * Triaged as Emergency Severity Index 4 or 5 * Presenting to the William Beaumont Army Medical Center Emergency Department with a chief complaint of acute MSK pain (i.e., general muscular, neck, back, shoulder, arm, forearm, elbow, wrist, finger, hip, knee, thigh, leg, ankle, foot, or digits) * Pain intensity of 20 mm or greater on a standard 100 mm visual analog scale * Who the attending provider concurred with ketorolac IM administration for analgesia. Exclusion Criteria: * Body weight less than 50 kg (110 lbs.) * Younger than 18 or older than 55 years * Pregnant or breast feeding * History of: confirmed, unconfirmed, known, unknown, or suspected peptic ulcer disease, intestinal hemorrhage, renal insufficiency, hepatic insufficiency, cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, dark stools, bright red blood per rectum, hemoptysis, easy bruising, or high risk of bleeding * Unable to confidently convey or unknown medical history * Allergy or hypersensitivity to nonsteroidal anti-inflammatory drugs or aspirin * Systolic blood pressure \<90 or \>180 mmHg * Pulse rate \<50 or \>150 beats/min * Any over-the-counter or prescribed opioid and/or non-opioid analgesic medication (oral, per rectum, topical or parenteral) taken within 12 hours of ED presentation * Advised by any medical provider to not receive NSAIDs for any reason * Pain duration greater than 30 days (including acute on chronic pain) * Refusal to remain in the WBAMC ED for up to 60 minutes after injection of ketorolac * Patients currently taking anticoagulant medications * Concurrent use of medications which are contraindicated with concomitant NSAID use (drugs include aspirin, probenecid and pentoxifylline).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adverse event are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia Emergencies Musculoskeletal Pain pain agnosia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adverse event Analgesia Musculoskeletal pain

Contacts and locations

Locations

  • William Beaumont Army Medical Center

    El Paso, Texas, 79920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.